Skip to main content
Digital Seminar

Emerging Psychedelic Treatments: Opportunities and Challenges

$199.99 Standard

Media reports about psychedelics are now more likely to be about emerging therapeutic uses than about raves or drug busts. Are your clients asking you about them, are you curious about their potential to enliven psychotherapy? Clinical trials of MDMA and psilocybin as catalysts to psychotherapy are in final stages of FDA trials. Results show large treatment effects for PTSD, depression, and relationship satisfaction in couples. In this treatment model, the drugs are administered only a few times in a course of psychotherapy aimed at accessing the individual’s own healing potential. Guided in this recording by the psychiatrist at the helm of the MDMA-assisted psychotherapy trials, you’ll explore:

  • The rationale for using drugs like MDMA as catalysts for psychotherapy
  • How to understand the clinical trial results
  • The MDMA-assisted psychotherapy process, illustrated with video clips
  • The challenges of maintaining quality and equitable access as these treatments approach likely FDA approval

Here's What You'll Learn

  • Background and effects of MDMA
    • Case reports of clinical use before MDMA was placed in schedule 1
    • Neurochemistry and physiological effects
       
  • Results of clinical trials of MDMA-assisted psychotherapy
    • Timeline of research in past 20 years
    • Results of Phase 2 and Phase 3 clinical trials
       
  • Psilocybin research
    • Brief review of indications studied in psilocybin clinical trials
    • Similarities and differences between therapeutic approaches in studies of psilocybin and studies of MDMA-assisted psychotherapy.
       
  • The therapeutic method used in MDMA trials
    • The therapy Manual
    • Adherence criteria
    • Clinical vignettes from Clinical Trials illustrated with quotes and video clips
       
  • The likely future roles of psychedelics in psychiatry and psychological

Everything You're Getting

  • More than 3 hours of video content
  • CE information to come
  • Handouts and resources

Meet Your Experts

Michael Mithoefer, MD

Toggle speaker biography

Michael Mithoefer, MD, is clinical assistant professor of psychiatry at the Medical University of South Carolina. In 2009, he completed & published the first FDA approved clinical trial of MDMA assisted psychotherapy for treatment-resistant PTSD, followed by completion of a Phase II trial. He is overseeing a multisite Phase III study of MDMA-assisted psychotherapy in 13 sites around the US (including the Trauma Research Foundation), and another MDMA-assisted psychotherapy multisite study in Europe and Israel.

 

Speaker Disclosures:
Financial: Dr. Michael Mithoefer has employment relationships with Columbia University, Bassett Healthcare Network, University of South Carolina, Lykos Therapeutics and has ownership interest in Awakn Life Sciences. He is a sub-investigator and therapist at Zen Therapeutics and a consultant with MAPS. Dr. Mithoefer receives a speaking honorarium and recording royalties from PESI, Inc.
Non-financial: Dr. Michael Mithoefer is a fellow of the American Psychiatric Association.
More taught by Michael Mithoefer, MD

Rick Doblin, PhD

Toggle speaker biography

Rick Doblin, PhD, is the founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS). His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and dog.

 

Speaker Disclosures:
Financial: Richard Doblin has an employment relationship with Multidisciplinary Association for Psychedelic Studies, Inc. He receives a speaking honorarium and recording royalties from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Richard Doblin serve on the Board of Lykos Therapuetics.

More taught by Rick Doblin, PhD

100% Satisfaction Guarantee

Register for this intensive training course without risk. If you're not completely satisfied, give us a call at 800-844-8260.

We’re that confident you'll find this learning experience to be all that's promised and more than you expected.

PESI App

Access CE trainings on your phone or tablet through our free mobile app. Choose video or audio-only versions of online courses from the world's best instructors, and complete your CE requirements anywhere, anytime, at your own pace.

Download on the App Store Get it on Google Play

Access for Self-Study (Non-Interactive)

Access never expires for this product.


For a more detailed outline that includes times or durations of time, if needed, please contact cepesi@pesi.com  

 

Questions?

Visit our FAQ page at www.pesi.com/faq or contact us at www.pesi.com/info

Want this training for your whole team?

Get a customized training package for your team at a discounted rate!

Learn More about team training packages
Media Type:
Digital Seminar
Product Code:
NOS096211
Duration:
3 hours, 55 minutes
Copyright:
Mar 12, 2022

ADA Needs

We would be happy to accommodate your ADA needs; please call our Customer Service Department for more information at 1-800-844-8260.

Some text some message..
Back to Top